1. Home
  2. EDUC vs IMNN Comparison

EDUC vs IMNN Comparison

Compare EDUC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Educational Development Corporation

EDUC

Educational Development Corporation

HOLD

Current Price

$1.30

Market Cap

10.8M

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.78

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDUC
IMNN
Founded
1965
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
12.9M
IPO Year
N/A
1985

Fundamental Metrics

Financial Performance
Metric
EDUC
IMNN
Price
$1.30
$3.78
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
18.6K
64.6K
Earning Date
01-09-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,415,900.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$2.99
52 Week High
$1.93
$41.22

Technical Indicators

Market Signals
Indicator
EDUC
IMNN
Relative Strength Index (RSI) 43.32 49.02
Support Level $1.26 $2.99
Resistance Level $1.35 $4.00
Average True Range (ATR) 0.07 0.30
MACD 0.00 -0.01
Stochastic Oscillator 39.39 62.79

Price Performance

Historical Comparison
EDUC
IMNN

About EDUC Educational Development Corporation

Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: